

Giacomo Laffi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/916982/publications.pdf>

Version: 2024-02-01

124
papers

8,160
citations

53751

45
h-index

48277

88
g-index

125
all docs

125
docs citations

125
times ranked

7426
citing authors

#	ARTICLE	IF	CITATIONS
1	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	1.8	38
2	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	4.2	6
3	Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis. <i>Internal and Emergency Medicine</i> , 2021, 16, 339-347.	1.0	4
4	Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes. <i>Internal and Emergency Medicine</i> , 2020, 15, 37-48.	1.0	50
5	Super-Resolution Microscopy Reveals an Altered Fibrin Network in Cirrhosis: The Key Role of Oxidative Stress in Fibrinogen Structural Modifications. <i>Antioxidants</i> , 2020, 9, 737.	2.2	9
6	Characterization of lymphocyte subsets in ascitic fluid and peripheral blood of decompensated cirrhotic patients with chronic hepatitis C and alcoholic liver disease: A pivotal study. <i>International Journal of Immunopathology and Pharmacology</i> , 2020, 34, 205873842092958.	1.0	1
7	Macro-aspartate aminotransferase in a healthy woman. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 378-381.	4.5	3
8	Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. <i>Current Medical Research and Opinion</i> , 2019, 35, 661-666.	0.9	3
9	Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study. <i>Digestive and Liver Disease</i> , 2019, 51, 870-874.	0.4	1
10	Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1153-1162.e7.	2.4	90
11	Aldoxorubicin and Temozolomide combination in a xenograft mice model of human glioblastoma. <i>Oncotarget</i> , 2018, 9, 34935-34944.	0.8	10
12	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	6.3	345
13	Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study. <i>World Journal of Hepatology</i> , 2018, 10, 409-416.	0.8	3
14	Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study. <i>European Journal of Pharmacology</i> , 2017, 806, 105-109.	1.7	24
15	Neuroendocrine Dysregulation in Irritable Bowel Syndrome Patients: A Pilot Study. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 428-434.	0.8	24
16	Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma. <i>Oncotarget</i> , 2017, 8, 89595-89606.	0.8	16
17	Assessment of liver fibrosis in primary biliary cholangitis: Comparison between indirect serum markers and fibrosis morphometry. <i>Digestive and Liver Disease</i> , 2016, 48, 298-301.	0.4	9
18	DRESS syndrome in a patient with chronic hepatic encephalopathy. <i>Turkish Journal of Gastroenterology</i> , 2016, 27, 391-394.	0.4	2

#	ARTICLE	IF	CITATIONS
19	Screening of distress among hospitalized patients in a department of internal medicine. <i>Asian Journal of Psychiatry</i> , 2015, 18, 91-96.	0.9	10
20	Dysregulated Intrahepatic CD4+ T-Cell Activation Drives Liver Inflammation in Ileitis-Prone SAMP1/YitFc Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 406-419.	2.3	6
21	Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. <i>Hepatology</i> , 2015, 61, 1145-1153.	3.6	107
22	Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. <i>World Journal of Gastroenterology</i> , 2015, 21, 3013.	1.4	12
23	Paradoxical embolization in TIPS: take a closer look to the heart. <i>Annals of Hepatology</i> , 2015, 14, 127-31.	0.6	2
24	n-3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis. <i>Liver International</i> , 2014, 34, 918-930.	1.9	17
25	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. <i>Journal of Translational Medicine</i> , 2014, 12, 21.	1.8	14
26	Serotonin and its implication in the side-effects of interferon-based treatment of patients with chronic viral hepatitis: Pharmacological interventions. <i>Hepatology Research</i> , 2014, 44, 9-16.	1.8	9
27	Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. <i>Digestive and Liver Disease</i> , 2014, 46, 833-837.	0.4	57
28	Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. <i>World Journal of Gastroenterology</i> , 2014, 20, 786.	1.4	24
29	Neuroendocrine markers and psychological features in patients with irritable bowel syndrome. <i>International Journal of Colorectal Disease</i> , 2013, 28, 1203-1208.	1.0	28
30	Diffusion-Weighted Imaging of the Liver: A Comprehensive Review. <i>Current Problems in Diagnostic Radiology</i> , 2013, 42, 77-83.	0.6	18
31	Acute on chronic liver failure: From pathophysiology to clinical management. <i>Trends in Anaesthesia and Critical Care</i> , 2013, 3, 122-129.	0.4	9
32	Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. <i>Digestive and Liver Disease</i> , 2013, 45, 840-843.	0.4	47
33	Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. <i>Hepatology</i> , 2013, 58, 65-72.	3.6	159
34	Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia. <i>PLoS ONE</i> , 2013, 8, e62965.	1.1	42
35	Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. <i>Journal of Gastroenterology</i> , 2012, 47, 1177-1185.	2.3	114
36	Hepato-systemic gradient of carbon monoxide in cirrhosis. <i>European Journal of Internal Medicine</i> , 2012, 23, e14-e18.	1.0	2

#	ARTICLE	IF	CITATIONS
37	The hepatitis C virus infection as a systemic disease. <i>Internal and Emergency Medicine</i> , 2012, 7, 201-208.	1.0	42
38	Noncontrast Functional MRI of the Kidneys. <i>Current Urology Reports</i> , 2012, 13, 99-107.	1.0	19
39	Non invasive continuous hemodynamic evaluation of cirrhotic patients after postural challenge. <i>World Journal of Hepatology</i> , 2012, 4, 149.	0.8	0
40	Elevated plasma levels of urotensin II do not correlate with systemic haemodynamics in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2011, 43, 314-318.	0.4	5
41	Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice. <i>Journal of Hepatology</i> , 2011, 55, 1241-1248.	1.8	87
42	Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: Role of polymorphic variants of BAFF promoter and Fcγ3 receptors. <i>Arthritis and Rheumatism</i> , 2011, 63, 1446-1451.	6.7	59
43	Curcumin limits the fibrogenic evolution of experimental steatohepatitis. <i>Laboratory Investigation</i> , 2010, 90, 104-115.	1.7	84
44	Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. <i>Blood</i> , 2010, 116, 335-342.	0.6	112
45	Increased Plasma Carbon Monoxide in Patients With Viral Cirrhosis and Hyperdynamic Circulation. <i>American Journal of Gastroenterology</i> , 2009, 104, 891-897.	0.2	26
46	Complete resolution of primary sclerosing peritonitis ("abdominal cocoon") following long term therapy for <i>Tropheryma whipplei</i> : a case report and review of literature. <i>BMJ Case Reports</i> , 2009, 2009, bcr0420091810-bcr0420091810.	0.2	5
47	Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. <i>Hepatology</i> , 2008, 47, 668-676.	3.6	118
48	Acute viral hepatitis increases liver stiffness values measured by transient elastography. <i>Hepatology</i> , 2008, 47, 380-384.	3.6	643
49	Hepatitis C virus (HCV) infection: A systemic disease. <i>Molecular Aspects of Medicine</i> , 2008, 29, 85-95.	2.7	80
50	Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. <i>Blood</i> , 2008, 111, 2943-2945.	0.6	24
51	Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia?. <i>Blood</i> , 2008, 112, 4353-4354.	0.6	25
52	Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. <i>Journal of Hepatology</i> , 2007, 46, 230-238.	1.8	93
53	Thrombocytopenia in chronic liver disease: Lessons from transplanted patients. <i>Journal of Hepatology</i> , 2007, 47, 625-629.	1.8	12
54	Effect of chronic hepatitis C virus infection on inflammatory lipid mediators. <i>Digestive and Liver Disease</i> , 2007, 39, S76-S82.	0.4	10

#	ARTICLE	IF	CITATIONS
55	HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. <i>Digestive and Liver Disease</i> , 2007, 39, S107-S111.	0.4	30
56	Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. <i>Digestive and Liver Disease</i> , 2007, 39, S129-S133.	0.4	18
57	Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. <i>Hepatology</i> , 2007, 45, 1290-1297.	3.6	628
58	Performance of Doppler ultrasound in the prediction of severe portal hypertension in hepatitis C virus-related chronic liver disease. <i>Liver International</i> , 2007, 27, 1379-1388.	1.9	29
59	Resistin as an Intrahepatic Cytokine. <i>American Journal of Pathology</i> , 2006, 169, 2042-2053.	1.9	142
60	Long-term albumin infusion improves survival in patients with cirrhosis and ascites: An unblinded randomized trial. <i>World Journal of Gastroenterology</i> , 2006, 12, 1403.	1.4	128
61	Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G120-G128.	1.6	19
62	Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. <i>Hepatology</i> , 2005, 42, 1339-1348.	3.6	310
63	Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis. <i>Clinical Science</i> , 2004, 106, 27-34.	1.8	23
64	The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C1 The authors thank Wanda Delogu and Nadia Navari for skillful technical help, Dr. Roberto G. Romanelli for help in collecting liver biopsy specimens, and Dr. Mario Strazzabosco (Ospedali Riuniti di Bergamo,) Tj ETQq0 0 0.rgBT /Overlock 10 T		
65	Point and interval estimations of circadian melatonin ephasis in Smith-Magenis syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2003, 57, 31-34.	2.5	8
66	Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. <i>Blood</i> , 2003, 102, 1196-1201.	0.6	99
67	Prevalence of <i>bcl-2</i> Rearrangement in Patients with Hepatitis C Virus-Related Mixed Cryoglobulinemia with or without B-Cell Lymphomas. <i>Annals of Internal Medicine</i> , 2002, 137, 571.	2.0	185
68	Impaired sympathetic regulation of cerebral blood flow in patients with cirrhosis of the liver. <i>Clinical Science</i> , 2002, 103, 43-51.	1.8	13
69	Impaired sympathetic regulation of cerebral blood flow in patients with cirrhosis of the liver. <i>Clinical Science</i> , 2002, 103, 43.	1.8	6
70	Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. <i>Journal of Hepatology</i> , 2002, 37, 39-47.	1.8	97
71	Cardiovascular effects of canrenone in patients with preascitic cirrhosis. <i>Hepatology</i> , 2002, 35, 1441-1448.	3.6	21
72	Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. <i>Hepatology</i> , 2001, 33, 713-721.	3.6	69

#	ARTICLE	IF	CITATIONS
73	The integrin, $\alpha_6\beta_1$, is necessary for the matrix-dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells. <i>Hepatology</i> , 2001, 34, 42-49.	3.6	59
74	Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. <i>Hepatology</i> , 2001, 34, 19-27.	3.6	81
75	Signal Transduction by the Chemokine Receptor CXCR3. <i>Journal of Biological Chemistry</i> , 2001, 276, 9945-9954.	1.6	272
76	Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on Ras in human hepatic stellate cells. <i>Hepatology</i> , 2000, 31, 131-140.	3.6	67
77	T(14;18) translocation in chronic hepatitis C virus infection. <i>Hepatology</i> , 2000, 31, 474-479.	3.6	157
78	Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. <i>Gastroenterology</i> , 2000, 119, 479-492.	0.6	108
79	Ligands of peroxisome proliferator-activated receptor β modulate profibrogenic and proinflammatory actions in hepatic stellate cells. <i>Gastroenterology</i> , 2000, 119, 466-478.	0.6	390
80	Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. <i>Translational Research</i> , 1999, 134, 68-73.	2.4	47
81	Monocyte chemoattractant protein-1 as a chemoattractant for human hepatic stellate cells. <i>Hepatology</i> , 1999, 29, 140-148.	3.6	253
82	Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by <i>In Vivo</i> liver injury in the rat. <i>Hepatology</i> , 1999, 30, 951-958.	3.6	161
83	Complications of cirrhosis: is endothelium guilty?. <i>Journal of Hepatology</i> , 1999, 30, 532-535.	1.8	8
84	Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. <i>Journal of Hepatology</i> , 1999, 30, 632-638.	1.8	42
85	Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. <i>Journal of Hepatology</i> , 1999, 30, 639-645.	1.8	235
86	Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication?. <i>Journal of Hepatology</i> , 1999, 31, 1087.	1.8	22
87	Effect of some cyclooxygenase inhibitors on the increase in guanosine 3',5'-cyclic monophosphate induced by NO-donors in human whole platelets. <i>British Journal of Pharmacology</i> , 1998, 123, 1457-1463.	2.7	6
88	Expression of the thrombin receptor in human liver: Up-regulation during acute and chronic injury. <i>Hepatology</i> , 1998, 27, 462-471.	3.6	95
89	Knockout of $\alpha_6\beta_1$ -integrin expression reverses the transformed phenotype of hepatocarcinoma cells. <i>Gastroenterology</i> , 1998, 115, 433-442.	0.6	43
90	Effects of supplementation with unsaturated fatty acids on plasma and membrane lipid composition and platelet function in patients with cirrhosis and defective aggregation. <i>Journal of Hepatology</i> , 1998, 28, 654-661.	1.8	12

#	ARTICLE	IF	CITATIONS
91	Autonomic Regulation of Heart Rate and QT Interval in Nonalcoholic Cirrhosis with Ascites. <i>Digestion</i> , 1997, 58, 580-586.	1.2	39
92	Cerebral autoregulation in patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 1997, 27, 114-120.	1.8	38
93	Defective aggregation in cirrhosis is independent of in vivo platelet activation. <i>Journal of Hepatology</i> , 1996, 24, 436-443.	1.8	34
94	Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites. <i>Journal of Hepatology</i> , 1996, 25, 481-490.	1.8	21
95	Treatment of Ascites in Cirrhosis. , 1996, , 286-295.		0
96	Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. <i>Hepatology</i> , 1995, 22, 1666-1673.	3.6	83
97	Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention. <i>Hepatology</i> , 1995, 22, 1745-1750.	3.6	26
98	Involvement of phosphatidylinositol 3-kinase in the activation of extracellular signal-regulated kinase by PDGF in hepatic stellate cells. <i>FEBS Letters</i> , 1995, 376, 141-145.	1.3	85
99	â€œInapparentâ€ hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease. <i>Hepatology</i> , 1994, 19, 577-582.	3.6	44
100	Biosynthesis of platelet-activating factor and its 1O-acyl analogue by liver fat-storing cells. <i>Gastroenterology</i> , 1994, 106, 1301-1311.	0.6	43
101	Torasemide in the treatment of patients with cirrhosis and ascites. <i>Cardiovascular Drugs and Therapy</i> , 1993, 7, 81-85.	1.3	26
102	Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. <i>Gastroenterology</i> , 1993, 105, 148-156.	0.6	62
103	Thromboxane-receptor blockade increases water diuresis in cirrhotic patients with ascites. <i>Gastroenterology</i> , 1992, 103, 1017-1021.	0.6	17
104	Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. <i>Gastroenterology</i> , 1992, 103, 641-646.	0.6	105
105	Pathophysiology and treatment of ascites and the hepatorenal syndrome. <i>Bailliere's Clinical Gastroenterology</i> , 1992, 6, 581-607.	0.9	23
106	Plasma levels of brain natriuretic peptide in patients with cirrhosis. <i>Hepatology</i> , 1992, 16, 156-161.	3.6	78
107	Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: A randomized, double-blind study. <i>Hepatology</i> , 1991, 13, 1101-1105.	3.6	43
108	Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. <i>Gastroenterology</i> , 1989, 96, 167-177.	0.6	67

#	ARTICLE	IF	CITATIONS
109	Renal Functional Impairment and Sodium Retention in Liver Cirrhosis. <i>Digestion</i> , 1989, 43, 1-32.	1.2	24
110	Effects of repeated atrial natriuretic peptide bolus injections in cirrhotic patients with refractory ascites. <i>Liver</i> , 1989, 9, 315-321.	0.1	11
111	Altered platelet function in cirrhosis of the liver: Impairment of inositol lipid and arachidonic acid metabolism in response to agonists. <i>Hepatology</i> , 1988, 8, 1620-1626.	3.6	84
112	Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites. <i>Gastroenterology</i> , 1988, 94, 1470-1477.	0.6	34
113	Intrarenal thromboxane A2 generation reduces the furosemide-induced sodium and water diuresis in cirrhosis with ascites. <i>Gastroenterology</i> , 1988, 95, 1081-1087.	0.6	16
114	Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance. <i>Gastroenterology</i> , 1987, 92, 294-298.	0.6	43
115	Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites. <i>Gastroenterology</i> , 1987, 92, 1859-1863.	0.6	41
116	Molecular mechanism underlying impaired platelet responsiveness in liver cirrhosis. <i>FEBS Letters</i> , 1987, 220, 217-219.	1.3	16
117	Systemic haemodynamics, renal and platelet function during chronic propranolol administration in patients with compensated cirrhosis. <i>Liver</i> , 1987, 7, 110-115.	0.1	12
118	Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1986, 90, 182-187.	0.6	90
119	Altered renal and platelet arachidonic acid metabolism in cirrhosis. <i>Gastroenterology</i> , 1986, 90, 274-282.	0.6	98
120	Assay methods for 6-keto-prostaglandin F ₁ ± in human urine. <i>Biomedical Applications</i> , 1985, 339, 1-9.	1.7	19
121	Sulindac and Indomethacin Suppress the Diuretic Action of Furosemide in Patients With Cirrhosis and Ascites: Evidence That Sulindac Affects Renal Prostaglandins. <i>American Journal of Kidney Diseases</i> , 1985, 6, 217-221.	2.1	39
122	Vasoactive factors in the mechanism of renal sodium handling in cirrhotics: The effect of acute plasma expansion. <i>Pharmacological Research Communications</i> , 1984, 16, 613-635.	0.2	1
123	Systemic Hemodynamics and Renal Function in Cirrhotic Patients during Plasma Volume Expansion. <i>Digestion</i> , 1983, 27, 138-145.	1.2	9
124	Atrial Natriuretic Peptide and Other Natriuretic Factors in Cirrhosis. , 0, , 73-83.		2